Advanced BioMedical Technologies, Inc.: 10-Q filed 2013-09-16

Name: Advanced BioMedical Technologies, Inc.: 10-Q filed 2013-09-16
Creator: Advanced BioMedical Technologies, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2013-09-16 (fiscal Q3 2013): 20 published measures, 86 facts as tagged in accession 0001354488-13-005225.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-09-16
Fiscal period: fiscal Q3 2013
Accession: 0001354488-13-005225 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-07-31	188,417	USD
At 2012-10-31	214,012	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-07-31	-2,718,256	USD
At 2012-10-31	-2,226,195	USD
At 2011-10-31	-1,562,770	USD
At 2010-10-31	-1,490,497	USD
At 2009-10-31	-1,262,757	USD
At 2008-10-31	-750,424	USD
At 2007-12-31	-515,317	USD
At 2006-12-31	-330,066	USD
At 2005-12-31	-158,076	USD
At 2004-12-31	340,280	USD
At 2003-12-31	434,864	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-07-31	37,976	USD
At 2012-10-31	49,092	USD
At 2012-07-31	43,442	USD
At 2011-10-31	78,781	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	-156,548	USD	92
2012-11-01 to 2013-07-31	-470,375	USD	273
2002-12-25 to 2013-07-31	-4,152,383	USD	3872
2011-11-01 to 2012-10-31	-758,525	USD	366
2012-05-01 to 2012-07-31	-190,879	USD	92
2011-11-01 to 2012-07-31	-550,442	USD	274
2010-11-01 to 2011-10-31	-487,439	USD	365
2009-11-01 to 2010-10-31	-816,799	USD	365
2008-11-01 to 2009-10-31	-558,432	USD	365
2008-01-01 to 2008-10-31	-227,038	USD	305
2007-01-01 to 2007-12-31	-196,871	USD	365
2006-01-01 to 2006-12-31	-191,014	USD	365
2005-01-01 to 2005-12-31	-511,233	USD	365
2004-01-01 to 2004-12-31	-94,229	USD	366
2003-01-01 to 2003-12-31	-57,633	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-11-01 to 2013-07-31	-438,571	USD	273
2002-12-25 to 2013-07-31	-3,097,416	USD	3872
2011-11-01 to 2012-07-31	-415,615	USD	274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-11-01 to 2013-07-31	4,127	USD	273
2002-12-25 to 2013-07-31	450,353	USD	3872
2011-11-01 to 2012-07-31	74,552	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-11-01 to 2013-07-31	430,037	USD	273
2002-12-25 to 2013-07-31	3,842,087	USD	3872
2011-11-01 to 2012-07-31	429,556	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2012-11-01 to 2013-07-31	-2,961	USD	273
2002-12-25 to 2013-07-31	-450,875	USD	3872
2011-11-01 to 2012-07-31	-49,355	USD	274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-07-31	128,488	USD
At 2012-10-31	141,613	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-07-31	59,407	USD
At 2012-10-31	70,729	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-07-31	2,906,673	USD
At 2012-10-31	2,440,207	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	113,226	USD	92
2012-11-01 to 2013-07-31	346,022	USD	273
2002-12-25 to 2013-07-31	3,981,044	USD	3872
2012-05-01 to 2012-07-31	160,509	USD	92
2011-11-01 to 2012-07-31	464,291	USD	274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	5,367	USD	92
2012-11-01 to 2013-07-31	28,153	USD	273
2002-12-25 to 2013-07-31	284,836	USD	3872
2012-05-01 to 2012-07-31	43,208	USD	92
2011-11-01 to 2012-07-31	73,378	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-07-31	56,574,850	shares
At 2012-10-31	56,574,850	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-07-31	1,689,381	USD
At 2012-10-31	1,671,956	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2013-07-31	-255,820	USD
At 2012-10-31	-215,042	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	-156,548	USD	92
2012-11-01 to 2013-07-31	-470,375	USD	273
2002-12-25 to 2013-07-31	-4,369,588	USD	3872
2012-05-01 to 2012-07-31	-190,879	USD	92
2011-11-01 to 2012-07-31	-550,442	USD	274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	-170,644	USD	92
2012-11-01 to 2013-07-31	-511,153	USD	273
2002-12-25 to 2013-07-31	-4,408,203	USD	3872
2012-05-01 to 2012-07-31	-167,833	USD	92
2011-11-01 to 2012-07-31	-547,323	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	101,260	USD	92
2012-11-01 to 2013-07-31	298,342	USD	273
2002-12-25 to 2013-07-31	3,386,047	USD	3872
2012-05-01 to 2012-07-31	110,699	USD	92
2011-11-01 to 2012-07-31	372,494	USD	274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2013-05-01 to 2013-07-31	6,599	USD	92
2012-11-01 to 2013-07-31	19,527	USD	273
2002-12-25 to 2013-07-31	310,161	USD	3872
2012-05-01 to 2012-07-31	6,602	USD	92
2011-11-01 to 2012-07-31	18,419	USD	274

Inspect the source

Entity: Advanced BioMedical Technologies, Inc. / CIK 0001385799
Captured: 2026-09-22 19:45 UTC
SEC response SHA-256: 1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))